NCT02652546 - CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 9, 2016

Primary Completion Date

May 15, 2017

Study Completion Date

November 2, 2018

Conditions

HIV, Inflammation

Interventions

DRUG

Assess Safety

Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia

DRUG

Effect of drug on viral load

Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points

DRUG

Effect of drug on T-cell count

Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points

DRUG

Effect of drug on inflammatory biomarkers

Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH